REG - GSK PLC - GSK US Investment Announcement

GSKAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250917:nRSQ6017Za&default-theme=true

RNS Number : 6017Z  GSK PLC  17 September 2025

Issued: 17 September 2025, London UK

 

GSK to invest $30 billion in R&D and Manufacturing in the United States
over next 5 years

 

·   Includes new $1.2 billion investment announced today in manufacturing
facilities, AI and advanced digital technologies, creating hundreds of highly
skilled U.S. jobs

·   New facilities will bridge R&D and manufacturing across both the
U.S. and U.K., strengthening the two countries' leadership in life sciences

 

 

GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion across the
United States in research and development and supply chain infrastructure over
the next five years.

 

This includes a new $1.2 billion investment in advanced manufacturing
facilities and AI and advanced digital technologies, to deliver new,
next-generation biopharma factories and laboratories in the United States.
These investments build on GSK's strong innovation and manufacturing footprint
and capabilities in the United States today, developing and making products in
the United States for the United States.

 

The $1.2 billion investment includes:

·      Construction of an additional new biologics flex factory at Upper
Merion, Pennsylvania to deliver potential best-in-class new medicines for
respiratory disease (COPD, asthma) and cancer (haematological, gynaecological,
lung and other solid tumours). Construction is planned to commence in 2026

·      New AI and advanced digital technology capabilities across GSK's
existing 5 manufacturing sites in 4 States (Pennsylvania, North Carolina,
Maryland, and Montana)

·      New drug substance manufacturing capabilities

·      New and enhanced device and auto-injector capabilities and
assembly

 

Commenting on the State Visit and today's announcement, GSK CEO Emma Walmsley
said: "Alongside the many longstanding and vital shared interests that connect
the U.K. and the United States, is advancing life sciences to get ahead of
disease. This week's State Visit brings together two countries that have led
the world in science and healthcare innovation.  We are proud to be part of
both. Here in the U.K., we continue to invest in a significant manufacturing
base and more than £1.5 billion in R&D every year. Today, we are
committing to invest at least $30 billion in the United States over the next 5
years, further bolstering the already strong R&D and supply chain we have
in the country. $1.2 billion of today's announcement includes construction of
an additional next-gen biologics "flex" factory, powered by AI, advanced
technologies and expert talent to produce transformational new respiratory and
cancer medicines for American patients."

 

The $30 billion investment in the U.S. includes capital investments across
GSK's U.S. supply chain, as well as increased investment in R&D drug
discovery and development and clinical trial activity, with the U.S. expected
to rank first globally for the number of studies, sites and clinical trials
participants conducted by GSK over the next five years.

 

Today's announcement means GSK has committed new investments of approximately
$2 billion in U.S. manufacturing over the last 12 months. In October 2024,
construction began of a new $800 million facility at GSK's Marietta,
Pennsylvania site, doubling the size and capacity of the site. These new
manufacturing investments will create hundreds of highly skilled jobs (in
addition to construction jobs), building upon GSK's approximately 15,000
strong U.S. workforce.

 

Last year, GSK's global supply chain network delivered 1.7 billion packs of
medicines and over 400 million vaccine doses to help towards our goal of
positively impacting the health of 2.5 billion people by the end of 2030.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Simon Steel        +44 (0) 20 8047 5502  (London)
                      Dan Smith          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGMLMVFGKZZ